Safety evaluation of ruxolitinib for treating myelofibrosis.


INTRODUCTION In 2005, the JAK2 V617F mutation was identified and found to be highly prevalent in the 'Philadephia Chromosome-negative' Myeloproliferative neoplasms (MPN). This led to new diagnostic criteria for MPN in addition to the development of the first targeted therapy for myelofibrosis (MF), ruxolitinib . AREAS COVERED Ruxolitinib was approved… (More)
DOI: 10.1517/14740338.2014.916273


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics